Recent Updates
Recently added Catalysts
TOVX Positive Sentiment Score: 75/100

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

Tuesday, May 14, 2024 2 min read
Key Takeaway: Theriva™ Biologics, a clinical-stage company focused on cancer therapeutics, will participate in the A.G.P. 2024 Virtual Healthcare Conference. The event will include a corporate update and a fireside chat scheduled for May 21, 2024, at 7:30 AM ET. The company is advancing a novel oncolytic adenovirus platform aimed at improving cancer treatment outcomes. This participation may enhance visibility among investors and the broader healthcare community.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious virtual healthcare conference.
  • Opportunity to provide a corporate update, possibly increasing investor interest.
  • Showcasing innovative therapeutic approaches targeting cancer.

Full Press Release Details

ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva™ Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company’s Management will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference.
A.G.P. 2024 Virtual Healthcare Conference
Format: Fireside Chat
Presentation Date: Tuesday, May 21, 2024
Presentation Time: 7:30 AM ET
About Theriva™ Biologics, Inc.
Theriva™ Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics’ website at www.therivabio.com.
For further information, please contact:
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
Source: Theriva Biologics, Inc.

Frequently Asked Questions

When is Theriva Biologics presenting at the conference?

Theriva Biologics will present on May 21, 2024, at 7:30 AM ET.

What type of therapies does Theriva Biologics develop?

Theriva Biologics develops therapeutics for cancer and related diseases.

What is the focus of Theriva's lead candidate VCN-01?

VCN-01 targets tumor cells selectively and aims to degrade the tumor stroma barrier.

How does SYN-004 help transplant recipients?

SYN-004 is designed to prevent microbiome damage and reduce acute graft-versus-host disease.

What is the purpose of SYN-020?

SYN-020 is intended to treat local GI and systemic diseases through oral administration.

Tags: TOVX Viatris Investor Conferences Healthcare Theriva Biologics A.G.P. Conference cancer therapeutics oncology
Last updated: May 14, 2024